Pfizer (NYSE:PFE) on Tuesday issued sales guidance of $67 billion to $71 billion for 2023, a decline from its record-breaking 2022 results.
The pharmaceutical company booked $100.3 billion for full-year 2022, an all-time high driven by more than $50 billion in COVID vaccine and antiviral sales.
Pfizer expects revenue for 2023 to decline up to 33% compared with 2022 as the pandemic eases and demand for its COVID portfolio slides. The company expects $13.5 billion in COVID vaccine sales in 2023 and $8 billion in revenue for Paxlovid.
Pfizer is forecasting 2023 earnings of $3.25 to $3.45 per share, as much as a 50% drop from its record $6.58 in 2022. The company booked net income $31.4 billion in 2022, a 43% increase over 2021.
Pfizer’s stock fell 3% in premarket trading.
The drugmaker’s results for the fourth quarter largely met analyst expectations. The company booked net income of nearly $5 billion for the quarter, a 47% increase over the same period in 2021. It generated $24.3 billion in revenue for the quarter.
Adjusted EPS proved to be $1.14 vs. $1.05 expected, on revenues of $24.3 billion vs. $24.28 billion
PFE shares took on a nickel to $43.60.
